ROP.SW Roche Holding AG
Company Analysis
Latest News
Roche eye implant nears EU approval, cutting injections to twice yearly
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for Roche’s Susvimo. The therapy treats neovascular...
🟢 Roche Holding is trading 5.1% up today amid sector-wide healthcare gains and rotation into medical research names
Roche Holding is trading 5.14% up now at CHF 349.50 following a sharp move that aligns with broader healthcare sector momentum rather than company-specific...
Roche Scraps Two Huntington’s Drugs, Citing Trial Failures
Roche discontinued two investigational Huntington's disease drugs, tominersen and RG6496, developed in collaboration with Ionis Pharmaceuticals. The Phase 2...
Roche to Reveal New Trontinemab Alzheimer’s Data, Advancing Diagnostics at AAIC
Roche will present new data at the Alzheimer’s Association International Conference 2026 (AAIC) in London. The event takes place from July 12 to July 15....
Roche Divarasib Beats Rival Lung Cancer Drugs in Phase III Trial
Roche reported positive results from its Phase III Krascendo 1 study evaluating the investigational cancer drug divarasib. The trial focused on patients with...
Roche launches Axelios sequencer, challenging Illumina with same-day results
Roche launched the Axelios 1 next-generation sequencing (NGS) platform on June 29. The system utilizes Sequencing by Expansion (SBX) technology to compete...
🟢 ROP.SW is trading 2.4% up today after FDA milestones for cancer drug and diagnostic
ROP.SW is trading 2.4% up at $335.20 after Roche reported key FDA milestones for a cancer drug and companion diagnostic, which investors appear to be viewing...
🔴 Roche Holding AG is trading 2.9% down today despite FDA acceptance of lymphoma combo treatment
Roche Holding AG is trading 2.9% down now at $317.10 even as investors digest encouraging oncology news regarding its lymphoma treatment pipeline. • The FDA...
Roche Chemo-Free Lymphoma Combo Gains FDA Review, Cutting Risk by 59%
The U.S. Food and Drug Administration (FDA) accepted Roche’s supplemental Biologics License Application for the combination of Lunsumio and Polivy. This...
Roche Tecentriq Wins FDA Priority Review, Slashing Colon Cancer Risk by 50%
The FDA granted Priority Review for Roche’s Tecentriq in combination with chemotherapy for stage III colon cancer. The application targets patients with...
Roche strikes $2.3 billion Nurix deal for cancer and immunology drugs
Roche and Nurix Therapeutics have entered an exclusive agreement to co-develop and co-commercialize bexobrutideg. The investigational drug is a Bruton’s...
Roche Inks $3 Billion Nurix Deal, Targeting Potential Best-in-Class Cancer Drug
Roche and Nurix Therapeutics are entering a global collaboration to co-develop and co-commercialize bexobrutide. This oral BTK degrader targets B-cell...
Roche Slams US Protectionism, Citing $50 Billion Investment Blackmail
Roche Chairman Severin Schwan warned of rising protectionism in the United States and China during the Swiss Economic Forum. He stated both nations leverage...
🟢 Roche Holding AG is trading 4% up today as investors rotate into defensive healthcare
Roche Holding AG is trading 4% up at $324.60 as investors rotate into defensive, value-oriented healthcare names amid a broader sell-off in high-valuation risk...